Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01679470 · ClinicalTrials.gov registry record · NA
Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
A NA study, sponsored by Nanospectra Biosciences.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01679470 is a NA study that was terminated before completion, run by Nanospectra Biosciences. The registered enrollment target is 1 participants.
The verdict
NCT01679470, a NA study, was terminated before completion, sponsored by Nanospectra Biosciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, single-center, single-dose efficacy pilot study of AuroLase Therapy in the treatment of subjects with primary and/or metastatic tumors of the lung where there is airway obstruction. In this study patients will be given a systemic IV infusion of particles and a subsequent escalating dose of laser radiation delivered by optical fiber via bronchoscopy.
Interventions
- DEVICE AuroLase Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01679470
The ClinicalTrials.gov registry entry for NCT01679470 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nanospectra Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AuroLase Therapy is the first listed.
NCT01679470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01679470 about?
NCT01679470 is a clinical study titled "Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors". This is an open-label, single-center, single-dose efficacy pilot study of AuroLase Therapy in the treatment of subjects with primary and/or metastatic tumors of the lung where there is airway obstruction. In this study patients will be given a systemic IV infusion of particles and a subsequent escal...
What is the current status of trial NCT01679470?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2012-10. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01679470?
The interventions under investigation include: AuroLase Therapy (DEVICE).
Who is sponsoring clinical trial NCT01679470?
This trial is sponsored by Nanospectra Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.